Shopping Cart 0
Cart Subtotal
AED 0

Glaucoma: Competitive Landscape to 2026

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 12827

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 25653

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 38480

Details

Glaucoma: Competitive Landscape to 2026

Summary

Glaucoma is a common, asymptomatic group of eye diseases that causes damage to the eye's optic nerve, resulting in progressive, irreversible vision loss. Glaucoma is one of the leading causes of blindness worldwide, especially in elderly people. In glaucoma patients, the IOP-the normal healthy eye pressure that is achieved when the eye produces a small amount of aqueous humor while letting an equal amount of fluid out of the eye-is disturbed due to mechanical compression and/or decreased blood flow to the optic nerve, thereby leading to increased IOP. This increased IOP damages the optic nerve fibers that send signals from the retina to the brain, resulting in blind spots in the vision field when a significant number of nerve fibers are damaged, and blindness when the entire nerve is destroyed. The exact cause of optic nerve damage from glaucoma is not yet clearly.

This report provides an assessment of the pipeline, clinical, and commercial landscape of Glaucoma. Overall, GlobalData expects new drug approvals to drive Glaucoma market growth over the next decade (2016-2026).

Scope

- Pipeline Assessment: regional breakdown, promising late-stage products, early-stage pipeline by molecule type

- Clinical Trials Assessment: trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics

- Commercial Assessment: leading marketed products, current and future players

- Competitive Landscape: Analysis-key market events (2016-2026).

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global Glaucoma market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Glaucoma market in the future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

READ MORE

Table Of Content

Scope

Table of Contents

1. Preface 2

1.1 Table of Contents 2

1.2 Abbreviations 3

1.3 Related Reports 4

2. Executive Summary 5

2.2 Key Findings 6

2.2 Key Events 7

3. Introduction 8

3.1 Report Scope 9-10

3.2 Disease Overview and Epidemiology 11-13

4. Pipeline Assessment 14

4.1 Pipeline Overview 15-16

4.2 Pipeline Breakdown by Region/Country 17

4.3 Pipeline Breakdown by Molecule Type and Target 18

4.4 Drug Review Designations 19

4.5 Products in Clinical Development 20-21

5. Clinical Trial Assessment 22

5.1 Clinical Trials Overview 23

5.2 Top Sponsors of Clinical Trials in Glaucoma 24-25

5.3 Trial Breakdown by Region 26

5.4 Therapy Area Perspective 27

5.5 Enrollment Analytics 28-30

6 Commercial Assessment 31

6.1 Leading Marketed Products 32

6.2 Current & Future Players 33

7. Competitive Landscape Analysis (2016-2026) 34

7.1 Events Classification Overview 35

7.2 US 36

7.3 5EU 37

7.4 Japan and China 38

8 Appendix 39

8.1 Sources 40

8.2 Methodology 41

8.3 Key Events Included in the Analysis 42

8.4 About the Authors 43-45

8.5 About GlobalData 46

8.6 Disclaimer 48

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

Aerie Pharmaceutical

Ocular Therapeutix

Allergan

Santen Pharmaceutical

Neurotech Pharmaeutical

Isarna Therapeutics

Senju Pharmaceutical

Wakamoto Pharmaceutical

Envisia Therapeutics

Lee's Pharmaceutical

Astellas

NicOx

Alcon

Pfizer

Kowa

Bausch + Lomb

Otsuka Pharmaceutical

Merck & Co.

InnFocus

ForSight VISION5

Company Profile

Company Profile Title

Glaucoma: Competitive Landscape to 2026

Summary

Glaucoma is a common, asymptomatic group of eye diseases that causes damage to the eye's optic nerve, resulting in progressive, irreversible vision loss. Glaucoma is one of the leading causes of blindness worldwide, especially in elderly people. In glaucoma patients, the IOP-the normal healthy eye pressure that is achieved when the eye produces a small amount of aqueous humor while letting an equal amount of fluid out of the eye-is disturbed due to mechanical compression and/or decreased blood flow to the optic nerve, thereby leading to increased IOP. This increased IOP damages the optic nerve fibers that send signals from the retina to the brain, resulting in blind spots in the vision field when a significant number of nerve fibers are damaged, and blindness when the entire nerve is destroyed. The exact cause of optic nerve damage from glaucoma is not yet clearly.

This report provides an assessment of the pipeline, clinical, and commercial landscape of Glaucoma. Overall, GlobalData expects new drug approvals to drive Glaucoma market growth over the next decade (2016-2026).

Scope

- Pipeline Assessment: regional breakdown, promising late-stage products, early-stage pipeline by molecule type

- Clinical Trials Assessment: trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics

- Commercial Assessment: leading marketed products, current and future players

- Competitive Landscape: Analysis-key market events (2016-2026).

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global Glaucoma market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Glaucoma market in the future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

READ MORE

Scope

Table of Contents

1. Preface 2

1.1 Table of Contents 2

1.2 Abbreviations 3

1.3 Related Reports 4

2. Executive Summary 5

2.2 Key Findings 6

2.2 Key Events 7

3. Introduction 8

3.1 Report Scope 9-10

3.2 Disease Overview and Epidemiology 11-13

4. Pipeline Assessment 14

4.1 Pipeline Overview 15-16

4.2 Pipeline Breakdown by Region/Country 17

4.3 Pipeline Breakdown by Molecule Type and Target 18

4.4 Drug Review Designations 19

4.5 Products in Clinical Development 20-21

5. Clinical Trial Assessment 22

5.1 Clinical Trials Overview 23

5.2 Top Sponsors of Clinical Trials in Glaucoma 24-25

5.3 Trial Breakdown by Region 26

5.4 Therapy Area Perspective 27

5.5 Enrollment Analytics 28-30

6 Commercial Assessment 31

6.1 Leading Marketed Products 32

6.2 Current & Future Players 33

7. Competitive Landscape Analysis (2016-2026) 34

7.1 Events Classification Overview 35

7.2 US 36

7.3 5EU 37

7.4 Japan and China 38

8 Appendix 39

8.1 Sources 40

8.2 Methodology 41

8.3 Key Events Included in the Analysis 42

8.4 About the Authors 43-45

8.5 About GlobalData 46

8.6 Disclaimer 48

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

Aerie Pharmaceutical

Ocular Therapeutix

Allergan

Santen Pharmaceutical

Neurotech Pharmaeutical

Isarna Therapeutics

Senju Pharmaceutical

Wakamoto Pharmaceutical

Envisia Therapeutics

Lee's Pharmaceutical

Astellas

NicOx

Alcon

Pfizer

Kowa

Bausch + Lomb

Otsuka Pharmaceutical

Merck & Co.

InnFocus

ForSight VISION5